With FDA's clearance, Kedrion can manufacture Ryplazim (plasminogen, human-tvmh), the first and only FDA-approved therapy for treating PLGD-1, at its Bolognana, Italy, site.
Nicholas Saraceno
Advertisement
Nicholas Saraceno is editor at Pharmaceutical Commerce.
Articles by Nicholas Saraceno
The company officially launched new production suites, a revamp of its development labs, and more at its Thousand Oaks, Calif., cell therapy manufacturing facility.
With this $3.6 million investment, the CDMO will strengthen its advanced labeling, automated visual inspection, and fill/finish technology.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
5